PositoAI/ US/ NeuroPace, Inc.

NeuroPace, Inc.

NasdaqGM: NPCE · Healthcare

Positivity Index

#6,290 / 6,774

Global

#3,588 / 4,000

United States

Positivity Score

-4,059

Rank→

Overview Go Deep Penta Pattern Funda News For this company Histo

PosiRed: no active red flags

NeuroPace, Inc. — Overview & Financial Snapshot

NeuroPace, Inc. (NasdaqGM: NPCE) is a Healthcare company, ranked #6,290 of 6,774 companies globally and #3,588 of 4,000 in United States on PositoAI, with a Positivity Score of -4,059. Its market capitalisation is ₹4,257.22 Cr ($451.02M), P/E ratio is -23.1 and P/B ratio is 37.96. It has no active red flags (PosiRed) or yellow flags (PosiYellow) on record.

For financial statements, ratio trends and score history, Go Deep →

Top-ranked Healthcare companies

#3 Dogwood Therapeutics, Inc. 27,827 #8 Impact BioMedical Inc. 26,149 #13 Onconetix, Inc. 25,902 #15 Revelation Biosciences, Inc. 25,780 #18 Vyome Holdings, Inc. 25,696

— Nothing to show —

OpenAI is reading recent news...

NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet which is used for prescribing and managing clinicians for programming implanted devices and managing patient care; and patient data management system, a secure online database that collects data that have been recorded by the RNS System; and nSight Platform, which provide clinicians with personalized patient reports, as well as programming suggestions. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.

P/B Ratio 37.96

P/E Ratio -23.1

D/E Ratio 5.88

ROE -103.27%

Owes vs Owns ? 0.88× High $0.88 owed for every $1 it owns · balance sheet Jun 2026

Dividend Yield 0.00%

Trailing EPS ₹-53.80$-0.57

Forward EPS ₹-20.53$-0.22

Beta 1.87

Market Cap ₹4,257.22 Cr$451.02M

What these numbers mean →

What does NeuroPace, Inc. do?

What is NeuroPace, Inc.'s P/E and P/B ratio?

NeuroPace, Inc. has a P/E ratio of -23.1 and a P/B ratio of 37.96.

What is NeuroPace, Inc.'s debt-to-equity ratio?

NeuroPace, Inc. has a debt-to-equity ratio of 5.88.

How much does NeuroPace, Inc. owe compared with what it owns?

NeuroPace, Inc. owes $0.88 for every $1 it owns (balance sheet Jun 2026), which is high.

What is NeuroPace, Inc.'s Positivity rank?

NeuroPace, Inc. is ranked #6,290 of 6,774 companies globally and #3,588 of 4,000 in United States on PositoAI, with a Positivity Score of -4,059.

Does NeuroPace, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?

No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for NeuroPace, Inc..

Where can I read the latest news about NeuroPace, Inc.?

Recent headlines about NeuroPace, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.

Does NeuroPace, Inc. have a PositoAI PosiShot or QR code?

Yes. A dated PosiShot of NeuroPace, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.

0 / 1000

🔒 Private — stored only in this browser, never sent to PositoAI. Clear anytime in Settings.